Cabaletta Bio, Inc

(NASDAQ:CABA)

Latest On Cabaletta Bio, Inc (CABA):

Date/Time Type Description Signal Details
2023-05-18 16:00 ESTNewsCabaletta Bio up 1%, prices $87M offeringN/A
2023-05-18 02:29 ESTNewsCabaletta Bio commences underwritten public offering of sharesN/A
2023-05-16 23:33 ESTNewsCabaletta Bio jumps 16% as FDA clears trial for myositis candidateN/A
2023-05-11 15:27 ESTNewsCabaletta Bio GAAP EPS of -$0.45 beats by $0.02N/A
2023-05-01 18:20 ESTNewsCabaletta's potential lupus drug CABA-201 gets FDA fast track tagN/A
2023-04-28 03:16 ESTNewsCabaletta Bio: Speculative Biotech With OpportunityN/A
2023-03-31 16:02 ESTNewsCabaletta CAR T cell therapy for lupus gets FDA nod to enter trialN/A
2023-03-31 16:02 ESTNews4 stocks to watch on Friday: Amazon, Kraft Heinz, and moreN/A
2023-03-16 13:19 ESTNewsCabaletta Bio GAAP EPS of -$0.52 misses by $0.08N/A
2023-01-27 17:59 ESTNewsCabaletta rises as Morgan Stanley upgrades citing new CAR-T assetN/A
2023-01-25 12:46 ESTNewsCabaletta: Adding To Position For 36% Return Potential After CABA-201 Rally (Technical Analysis)N/A
2022-12-08 20:30 ESTNewsCabaletta Bio dips on announcing $35M offeringN/A
2022-11-10 11:40 ESTNewsCabaletta Bio GAAP EPS of -$0.39 beats by $0.09N/A
2022-08-30 16:03 ESTNewsCabaletta downgraded at Morgan Stanley on upcoming data for lead assetN/A
2022-08-11 21:46 ESTNewsCabaletta Bio GAAP EPS of -$0.45 beats by $0.05N/A
2022-05-18 20:14 ESTNewsCabaletta Bio updates Phase 1 interim data for lead assetN/A
2022-05-12 11:04 ESTNewsCabaletta Bio GAAP EPS of -$0.45N/A
2022-03-18 09:46 ESTNewsCabaletta Bio GAAP EPS of -$0.49 beats by $0.11N/A
2021-12-14 08:41 ESTNewsCabaletta Bio tanks 34% on cell therapy data in early-stage study for pemphigus vulgarisN/A
2021-11-01 14:01 ESTNewsCabaletta Bio EPS beats by $0.05N/A
2021-11-01 14:01 ESTNewsCabaletta rises as skin diseases drug shown to be safe in early data of phase 1 trialN/A
2021-08-19 00:00 ESTNewsCabaletta Bio reports results from DesCAARTes trial in patients with pemphigus vulgarisN/A
2021-08-05 20:25 ESTNewsCabaletta Bio EPS beats by $0.03N/A
2021-03-18 15:25 ESTAnalyst RatingThe Analyst Target Price has increased from $20.33 to $22.25.Buy
2021-03-18 07:46 ESTFinancialsCompany financials have been released.Neutral
2021-03-17 17:01 ESTNewsCabaletta Bio EPS misses by $0.04N/A
2021-03-17 15:39 ESTEarnings EstimateAn EPS average of -$0.46 is estimated for the quarter ending on June 30, 2021.Sell
2021-03-17 15:39 ESTEarnings EstimateAn EPS average of -$2.18 is estimated for the 2022 year.Sell
2021-01-20 12:58 ESTNewsCabaletta: DSG3-CAART's 1H 2021 Data Release Can Substantiate This Young BiotechN/A
2021-01-11 10:22 ESTAnalyst RatingThe Analyst Target Price has increased from $20 to $20.33.Buy
2021-01-09 03:37 ESTNewsChardan Capital initiates Cabaletta Bio with Buy ratingN/A
2020-12-10 06:47 ESTNewsDosing underway in Cabaletta Bio's DSG3-CAART study in a rare skin blistering disorderN/A
2020-12-04 06:26 ESTFinancialsCompany financials have been released.Neutral
2020-11-27 00:46 ESTFinancialsCompany financials have been released.Neutral
2020-11-24 15:51 ESTAnalyst RatingThe Analyst Target Price has decreased from $21.67 to $20.Neutral
2020-11-17 07:28 ESTFinancialsCompany financials have been released.Neutral
2020-11-14 23:46 ESTFinancialsCompany financials have been released.Neutral
2020-11-12 07:15 ESTFinancialsCompany financials have been released.Neutral
2020-11-11 09:52 ESTNewsCabaletta Bio EPS beats by $0.08N/A
2020-11-11 09:52 ESTNewsCabaletta Bio +5% on Q3 results, pipeline updateN/A
2020-11-11 06:54 ESTEarnings EstimateAn EPS average of -$0.44 is estimated for the quarter ending on March 31, 2021.Sell
2020-10-15 08:02 ESTNewsCabaletta Bio (CABA) Investor Presentation - SlideshowN/A
2020-10-14 11:22 ESTAnalyst RatingThe Analyst Target Price has decreased from $22.5 to $21.67.Neutral
2020-10-08 21:07 ESTFinancialsCompany financials have been released.Neutral
2020-10-04 15:25 ESTFinancialsCompany financials have been released.Neutral
2020-09-26 16:38 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 09:18 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 12:44 ESTFinancialsCompany financials have been released.Neutral
2020-08-10 03:29 ESTFinancialsCompany financials have been released.Neutral
2020-08-07 23:40 ESTFinancialsCompany financials have been released.Neutral

About Cabaletta Bio, Inc (CABA):

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also include MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. Cabaletta Bio, Inc. has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was founded in 2017 and is headquartered in Philadelphia, Pennsylvania.

See Advanced Chart

General

  • Name Cabaletta Bio, Inc
  • Symbol CABA
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 31
  • Fiscal Year EndDecember
  • IPO Date2019-10-25
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Web URLhttp://www.cabalettabio.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 2.23
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$2.13
  • Next Year EPS Estimate -$2.45
  • Next Quarter EPS Estimate -$0.42
  • Return on Assets -17%
  • Return on Equity -27%
  • Earnings Per Share -$0.94
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 276.24 million
  • Analyst Target Price $22.25
View More

Share Statistics

  • Shares Outstanding 24.06 million
  • Shares Float 7.91 million
  • % Held by Insiders 523%
  • % Held by Institutions 67.4%
  • Shares Short 1.63 million
  • Shares Short Prior Month 1.61 million
  • Short Ratio 15.52
  • Short % of Float 8%
  • Short % of Shares Outstanding 7%
View More

Technicals

  • 52 Week High $16.38
  • 52 Week Low $6.07
  • 50 Day Moving Average 11.96
  • 200 Day Moving Average 12.4
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Cabaletta Bio, Inc (CABA) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Cabaletta Bio, Inc (CABA) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-16$N/A-$0.40-$0.36-11.11%
2020-09-302020-11-10$N/A-$0.36-$0.4418.18%
2020-06-302020-08-06$N/A-$0.35-$0.3910.26%
2020-03-312020-05-12$N/A-$0.33-$0.23-43.48%
2019-12-312020-03-30$N/A-$0.33-$0.4729.79%
2019-09-302019-12-05$N/A-$1.21-$2.2646.46%

Cabaletta Bio, Inc (CABA) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development 5.78 million N/A N/A 4.62 million 3.03 million
Income Before Tax -9.31 million N/A N/A -7.49 million -5.4 million
Selling General Administrative 3.56 million N/A N/A 3.28 million 2.83 million
Gross Profit N/A N/A N/A N/A N/A
Ebit -9.22 million N/A N/A -7.82 million -5.81 million
Operating Income -9.33 million N/A N/A -7.9 million -5.86 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A N/A N/A N/A
Net Income From Continuing Operations -9.31 million N/A N/A -7.49 million -5.4 million
Net Income Applicable to Common Shares -9.31 million -8.39 million -8.15 million N/A -5.4 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments 1.47 million N/A -226000 -273000 -40000
Change to Liabilities N/A -978000 N/A -306000 672000
Total Cash Flow from Investing Activities N/A -11.12 million N/A -273000 -40000
Net Borrowings N/A N/A N/A N/A N/A
Total Cash Flow from Financial Activities 135000 N/A -44000 73.32 million -2.1 million
Change to Operating Activities N/A 315000 N/A -3.04 million 1.3 million
Change in Cash -3.42 million N/A -5.2 million 65.16 million -4.22 million
Total Cash from Operating Activities -5.02 million -7.64 million -4.93 million -7.88 million -2.08 million
Depreciation 90000 N/A 76000 51000 32000
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities N/A -147000 N/A 2.1 million -2.1 million
Change to Net Income N/A 1.1 million N/A 819000 569000
Capital Expenditures 162000 N/A 226000 273000 40000
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities 5.18 million 4.27 million N/A 3.26 million 3.15 million
Total Stockholder Equity 109.54 million 117.51 million N/A 131.71 million 138.32 million
Other Current Liabilities 38000 140000 N/A 101000 177000
Total Assets 114.72 million 121.77 million N/A 134.97 million 141.47 million
Common Stock N/A N/A N/A N/A N/A
Other Current Assets 1.85 million N/A N/A N/A N/A
Retained Earnings -66.3 million -56.99 million -48.6 million -40.44 million -32.96 million
Other Liabilities N/A N/A N/A N/A N/A
Other Assets 299000 N/A 238000 N/A 101000
Cash 101.43 million 108.68 million N/A 131 million 136.2 million
Total Current Liabilities 5.18 million 4.27 million N/A 3.26 million 3.15 million
Other Stockholder Equity 6000 N/A 11000 N/A N/A
Property, Plant & Equipment 890000 N/A 806000 N/A 815000
Total Current Assets 113.54 million 119.22 million N/A 134.12 million 140.55 million
Long Term Investments N/A 1.33 million N/A N/A N/A
Net Tangible Assets 109.54 million N/A 124.64 million N/A 138.32 million
Short Term Investments 7.23 million 8.06 million N/A N/A N/A
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 1.24 million 953000 N/A 1.99 million 920000

Cabaletta Bio, Inc (CABA) Chart:

Cabaletta Bio, Inc (CABA) News:

Below you will find a list of latest news for Cabaletta Bio, Inc (CABA) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Cabaletta Bio, Inc (CABA) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2026-06-180.50CALL0 00TRUE00
2026-06-1810CALL0 0327.65TRUE00
2026-06-181.52.55CALL0 10TRUE00
2026-06-1821.4CALL0 900TRUE00
2026-06-182.51.05CALL0 54142.16TRUE00
2026-06-1830.6CALL0 516109.62TRUE00
2026-06-183.50.4CALL177 105382.8TRUE-0.05-0.11
2026-06-1840.24CALL264 250895.3FALSE00
2026-06-184.50.15CALL41 423104.67FALSE0.081.14
2026-06-1850.05CALL0 39122.3FALSE00
2026-06-185.50.07CALL0 100110.49FALSE00
2026-06-187.50.05CALL0 1327.52FALSE00
2026-06-180.50.04PUT0 6437.14FALSE00
2026-06-1810PUT0 0427.77FALSE00
2026-06-181.50PUT0 0552.85FALSE00
2026-06-1820.05PUT0 7143.47FALSE00
2026-06-182.50.25PUT0 504132.01FALSE00
2026-06-1830.05PUT0 36993.7FALSE00
2026-06-183.50.3PUT302 29398.59FALSE0.30
2026-06-1840.5PUT6 5873.61TRUE-0.1-0.17
2026-06-184.50.8PUT0 30107.65TRUE00
2026-06-1851.35PUT0 10134.31TRUE00
2026-06-185.50PUT0 0115.76TRUE00
2026-06-187.54.1PUT0 00TRUE00
2026-07-170.50CALL0 0346.82TRUE00
2026-07-1710CALL0 00TRUE00
2026-07-171.52.45CALL40 7290.56TRUE0.20.09
2026-07-1721.96CALL32 22217.44TRUE0.110.06
2026-07-172.51.23CALL0 26142.75TRUE00
2026-07-1730.67CALL0 472163.73TRUE00
2026-07-173.50.3CALL0 59279.13TRUE00
2026-07-1740.4CALL25 81293.43FALSE-0.02-0.05
2026-07-174.50.5CALL0 576.63FALSE00
2026-07-1750.3CALL0 209134.86FALSE00
2026-07-175.50.05CALL0 5184.08FALSE00
2026-07-177.50.38CALL0 5224.75FALSE00
2026-07-170.50.3PUT0 90FALSE00
2026-07-1710PUT0 0548.13FALSE00
2026-07-171.50PUT0 0381.04FALSE00
2026-07-1720PUT0 1283.4FALSE00
2026-07-172.50PUT0 0146.5FALSE00
2026-07-1730.55PUT0 5156.28FALSE00
2026-07-173.50.47PUT0 262124.36FALSE00
2026-07-1740.7PUT0 10079.14TRUE00
2026-07-174.51.2PUT0 285.75TRUE00
2026-07-1751.4PUT0 3105.1TRUE00
2026-07-175.50PUT0 0121.28TRUE00
2026-07-177.50PUT0 0155.95TRUE00
2026-08-210.53.11CALL0 3269.13TRUE00
2026-08-2110CALL0 00TRUE00
2026-08-211.52.5CALL32 9243.34TRUE0.250.11
2026-08-2121.95CALL41 39166.13TRUE0.140.08
2026-08-212.51CALL0 26012110.28TRUE00
2026-08-2131.15CALL19 3873118.59TRUE0.150.15
2026-08-213.50.75CALL0 10693.78TRUE00
2026-08-2140.65CALL0 7975.83FALSE00
2026-08-214.50.55CALL0 48106.61FALSE00
2026-08-2150.4CALL3 276108.54FALSE0.40
2026-08-215.50CALL0 9136.31FALSE00
2026-08-217.50CALL0 931175.28FALSE00
2026-08-210.50.25PUT1 5491.71FALSE0.250
2026-08-2110PUT0 0429.64FALSE00
2026-08-211.50PUT0 0298.75FALSE00
2026-08-2120PUT0 0222.33FALSE00
2026-08-212.50.23PUT0 37198.09FALSE00
2026-08-2130.3PUT0 107131.42FALSE00
2026-08-213.50PUT0 098.08FALSE00
2026-08-2140.9PUT0 4290.67TRUE00
2026-08-214.51.3PUT0 1090.43TRUE00
2026-08-2150PUT0 1999.32TRUE00
2026-08-215.50PUT0 0104.93TRUE00
2026-08-217.50PUT0 0124.9TRUE00
2026-09-180.50CALL0 8233.63TRUE00
2026-09-1812.42CALL0 14147.35TRUE00
2026-09-181.52.54CALL28 81223.78TRUE0.140.06
2026-09-1822.05CALL32 620167.31TRUE0.120.06
2026-09-182.51.15CALL0 6750114.44TRUE00
2026-09-1831.19CALL0 3638117.8TRUE00
2026-09-183.50.6CALL0 397100.69TRUE00
2026-09-1840.9CALL1 131123.69FALSE0.130.17
2026-09-184.50.46CALL0 65129.01FALSE00
2026-09-1850.47CALL0 354119.11FALSE00
2026-09-185.50.45CALL0 51118.7FALSE00
2026-09-187.50.37CALL0 996156.02FALSE00
2026-09-180.50.25PUT0 110FALSE00
2026-09-1810PUT0 0376.02FALSE00
2026-09-181.50PUT0 1254.05FALSE00
2026-09-1820PUT0 0194.72FALSE00
2026-09-182.50.35PUT0 40146.66FALSE00
2026-09-1830.51PUT0 48130.18FALSE00
2026-09-183.50PUT0 7118.72FALSE00
2026-09-1841.22PUT0 37116.51TRUE00
2026-09-184.50PUT0 1116.41TRUE00
2026-09-1850PUT0 8106.77TRUE00
2026-09-185.50PUT0 0112.7TRUE00
2026-09-187.50PUT0 0111.05TRUE00
2026-11-200.53.66CALL0 1185.94TRUE00
2026-11-2012.58CALL0 5114.88TRUE00
2026-11-201.50CALL0 099.87TRUE00
2026-11-2022.19CALL30 17159.26TRUE0.240.12
2026-11-202.51.5CALL0 233120.4TRUE00
2026-11-2030CALL0 11106.07TRUE00
2026-11-203.50.9CALL0 44112.38TRUE00
2026-11-2041.25CALL10 34135.02FALSE1.250
2026-11-204.51.5CALL0 7108.33FALSE00
2026-11-2050.5CALL0 31119.9FALSE00
2026-11-205.50.71CALL0 892114.99FALSE00
2026-11-207.50CALL0 0122.83FALSE00
2026-11-200.50.25PUT0 100FALSE00
2026-11-2010PUT0 0305.08FALSE00
2026-11-201.50.28PUT0 1212.28FALSE00
2026-11-2020PUT0 1158.23FALSE00
2026-11-202.50PUT0 256133.84FALSE00
2026-11-2030PUT0 10112.23FALSE00
2026-11-203.50PUT0 0118.68FALSE00
2026-11-2040PUT0 0110.59TRUE00
2026-11-204.51.6PUT0 20110.33TRUE00
2026-11-2050PUT0 0112.66TRUE00
2026-11-205.50PUT0 0113.12TRUE00
2026-11-207.50PUT0 0127.99TRUE00
2027-01-150.50CALL0 1160.33TRUE00
2027-01-1512.65CALL0 14144.39TRUE00
2027-01-151.52.45CALL1 178136.38TRUE-0.18-0.07
2027-01-1522.4CALL36 119172.09TRUE0.20.09
2027-01-152.51.8CALL0 554110.67TRUE00
2027-01-1531.69CALL0 862146.86TRUE00
2027-01-153.51.2CALL0 47126.87TRUE00
2027-01-1541.35CALL1 198126.72FALSE0.050.04
2027-01-154.51.35CALL0 26147.67FALSE00
2027-01-1551.3CALL51 1553143.53FALSE0.250.24
2027-01-155.50.73CALL0 165125.62FALSE00
2027-01-157.51.04CALL0 1115.92FALSE00
2027-01-150.50.25PUT2 7305.86FALSE0.250
2027-01-1510PUT0 0267.73FALSE00
2027-01-151.50PUT0 12186.37FALSE00
2027-01-1520.57PUT0 256139.04FALSE00
2027-01-152.50.66PUT0 266143.42FALSE00
2027-01-1530.84PUT0 6125.95FALSE00
2027-01-153.51.37PUT0 71129.28FALSE00
2027-01-1540PUT0 50125.09TRUE00
2027-01-154.50PUT0 2128.43TRUE00
2027-01-1550PUT0 5125.69TRUE00
2027-01-155.50PUT0 50113.25TRUE00
2027-01-157.54.32PUT0 200122.94TRUE00
2028-01-210.53CALL0 19141.62TRUE00
2028-01-2112.5CALL0 1148.88TRUE00
2028-01-211.52.6CALL0 96129.37TRUE00
2028-01-2122.45CALL0 411149.59TRUE00
2028-01-212.52.7CALL3 374151.39TRUE2.70
2028-01-2132.35CALL2 439128.38TRUE-0.05-0.02
2028-01-213.52.17CALL0 71141.57TRUE00
2028-01-2142.02CALL0 208140.56FALSE00
2028-01-214.52.25CALL0 12114.75FALSE00
2028-01-2152.2CALL2 183144.33FALSE2.20
2028-01-215.51.55CALL0 220152.56FALSE00
2028-01-210.50.17PUT1 7161.5FALSE0.170
2028-01-2110PUT0 0183.54FALSE00
2028-01-211.50PUT0 0133.79FALSE00
2028-01-2120PUT0 10137.95FALSE00
2028-01-212.50PUT0 49143.48FALSE00
2028-01-2131.6PUT0 806116.1FALSE00
2028-01-213.52.1PUT0 15143.2FALSE00
2028-01-2142.6PUT0 2139.78TRUE00
2028-01-214.50PUT0 0143.46TRUE00
2028-01-2153PUT0 80142.73TRUE00
2028-01-215.50PUT0 2141.63TRUE00

Latest CABA Trades:

Date Shares Price
Jun 13, 2022 7:37 PM EST1$1.08
Jun 13, 2022 7:37 PM EST6$1.08
Jun 13, 2022 7:51 PM EST7$1.06
Jun 13, 2022 7:57 PM EST7$1.06
Jun 13, 2022 7:58 PM EST7$1.055

Cabaletta Bio, Inc (CABA) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520159049/0001193125-20-159049-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319025941/0000899243-19-025941-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319025942/0000899243-19-025942-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319025943/0000899243-19-025943-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319025946/0000899243-19-025946-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319025947/0000899243-19-025947-index.htm
2019-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319026016/0000899243-19-026016-index.htm
2019-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319026017/0000899243-19-026017-index.htm
2019-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319026018/0000899243-19-026018-index.htm
2019-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319026020/0000899243-19-026020-index.htm
2019-10-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319026345/0000899243-19-026345-index.htm
2019-10-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319026346/0000899243-19-026346-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924320004509/0000899243-20-004509-index.htm
2020-02-135Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924320004511/0000899243-20-004511-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924320006864/0000899243-20-006864-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924320006865/0000899243-20-006865-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924320006867/0000899243-20-006867-index.htm
2020-09-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924320025326/0000899243-20-025326-index.htm
2020-07-21SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000090266420002724/0000902664-20-002724-index.htm
2019-11-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000092963819000988/0000929638-19-000988-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000092963820000331/0000929638-20-000331-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000110465919056233/0001104659-19-056233-index.htm
2019-10-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000110465919057348/0001104659-19-057348-index.htm
2019-10-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000110465919058504/0001104659-19-058504-index.htm
2019-11-12SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1759138/000110465919061822/0001104659-19-061822-index.htm
2019-10-24S-1MEFRegistration adding securities to prior Form S-1 registration [Rule 462(b)]https://www.sec.gov/Archives/edgar/data/1759138/000119312519273939/0001193125-19-273939-index.htm
2019-10-25424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1759138/000119312519274807/0001193125-19-274807-index.htm
2019-10-29S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1759138/000119312519277804/0001193125-19-277804-index.htm
2019-10-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312519278927/0001193125-19-278927-index.htm
2019-11-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000119312519287367/0001193125-19-287367-index.htm
2020-01-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520005110/0001193125-20-005110-index.htm
2020-01-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520017724/0001193125-20-017724-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000119312520038349/0001193125-20-038349-index.htm
2020-02-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520042689/0001193125-20-042689-index.htm
2020-03-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520090013/0001193125-20-090013-index.htm
2020-03-30S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1759138/000119312520091086/0001193125-20-091086-index.htm
2020-04-23DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1759138/000119312520115863/0001193125-20-115863-index.htm
2020-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520134391/0001193125-20-134391-index.htm
2020-05-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520139782/0001193125-20-139782-index.htm
2020-05-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520153792/0001193125-20-153792-index.htm
2020-06-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520159049/0001193125-20-159049-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520211336/0001193125-20-211336-index.htm
2019-10-30SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000119380519001374/0001193805-19-001374-index.htm
2019-10-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000119380519001376/0001193805-19-001376-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000119380520000185/0001193805-20-000185-index.htm
2019-12-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1759138/000156459019045375/0001564590-19-045375-index.htm
2020-03-3010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1759138/000156459020013929/0001564590-20-013929-index.htm
2020-05-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1759138/000156459020024508/0001564590-20-024508-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1759138/000156459020037278/0001564590-20-037278-index.htm
2019-10-24EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1759138/999999999519002384/9999999995-19-002384-index.htm

Cabaletta Bio, Inc (CABA) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Cabaletta Bio, Inc (CABA). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 523%
Institutional Ownership: 6740%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-10-295AM Ventures V, L.P.10% Share HolderBuy454,545.0011.004,999,995.00454,545.00https://www.sec.gov/Archives/edgar/data/1759138/000110465919058504/0001104659-19-058504-index.htm
2019-10-29James E Flynn10% Share HolderBuy700,000.0011.007,700,000.00700,000.00https://www.sec.gov/Archives/edgar/data/1759138/000119380519001376/0001193805-19-001376-index.htm